JP Morgan Chase
BHVN

JP Morgan Chase’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

JP Morgan Chase’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,041,718
Closed -$309M – 7422
2022
Q3 		$309M Buy
2,041,718
+1,165,134
+133% +$173M 0.04% 377
2022
Q2 		$128M Sell
876,584
-492,949
-36% -$63M 0.02% 654
2022
Q1 		$162M Sell
1,369,533
-25,592
-2% -$3.19M 0.02% 635
2021
Q4 		$192M Sell
1,395,125
-64,614
-4% -$8.22M 0.02% 583
2021
Q3 		$203M Sell
1,459,739
-292,129
-17% -$36.5M 0.03% 571
2021
Q2 		$170M Sell
1,751,868
-2,588
-0.1% -$210K 0.02% 658
2021
Q1 		$120M Buy
1,754,456
+78,494
+5% +$6.35M 0.02% 765
2020
Q4 		$144M Buy
1,675,962
+14,551
+0.9% +$1.23M 0.02% 642
2020
Q3 		$105M Buy
1,661,411
+53,557
+3% +$3.51M 0.02% 678
2020
Q2 		$118M Buy
1,607,854
+72,409
+5% +$3.85M 0.02% 602
2020
Q1 		$52.3M Buy
1,535,445
+100,852
+7% +$4.61M 0.01% 787
2019
Q4 		$78.1M Sell
1,434,593
-99,851
-7% -$4.94M 0.01% 763
2019
Q3 		$64M Sell
1,534,444
-12,268
-0.8% -$518K 0.01% 833
2019
Q2 		$65.8M Sell
1,546,712
-222,901
-13% -$12.6M 0.01% 847
2019
Q1 		$91.1M Sell
1,769,613
-126,347
-7% -$5.46M 0.02% 683
2018
Q4 		$70.1M Buy
1,895,960
+363,599
+24% +$13.1M 0.02% 752
2018
Q3 		$57.5M Buy
1,532,361
+105,913
+7% +$3.9M 0.01% 945
2018
Q2 		$56.4M Buy
1,426,448
+509,105
+55% +$16.2M 0.01% 902
2018
Q1 		$23.6M Sell
917,343
-1,937
-0.2% -$57.9K 0.01% 1389
2017
Q4 		$24.8M Buy
919,280
+441,027
+92% +$12.1M 0.01% 1419
2017
Q3 		$18.2M Sell
478,253
-114,972
-19% -$3.49M ﹤0.01% 1570
2017
Q2 		$14.8M Buy
+593,225
New +$13.7M ﹤0.01% 1664

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

JP Morgan Chase's BHVN Position: Q4 2022 in Review

JP Morgan Chase sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 2,041,718 shares — an estimated $309M sold.

JP Morgan Chase first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $309M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • JP Morgan Chase reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Chase sold 2,041,718 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $309M.
  • JP Morgan Chase first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • JP Morgan Chase's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $309M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.